BIOMERICA INC BMRA
Last close
2.31
2026-09-04
Market cap
$10.6M
2026-05-31 share count
52-week range
1.45 - 3.21
Valuation FY2025 figures against the last close
P/S2.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.30
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M | $5.2M | $5.6M | $5.8M |
| Cost of revenue | $4.1M | $4.8M | $4.8M | $4.9M | $15.9M | $6.8M | $5.0M | $3.9M | $3.8M | $3.8M |
| Gross profit | $362.0K | $498.0K | $611.0K | $446.0K | $3.0M | $366.3K | $1.7M | $1.3M | $1.8M | $2.0M |
| R&D | $788.0K | $1.0M | $1.5M | $1.6M | $1.8M | $2.2M | $1.9M | $1.7M | $1.4M | $1.1M |
| SG&A | $4.9M | $4.6M | $5.5M | $6.1M | $5.7M | $5.7M | $2.5M | $2.0M | $1.8M | $1.8M |
| Total operating expenses | $5.7M | $5.6M | $7.0M | $7.7M | $7.5M | $7.9M | $4.5M | $3.7M | $3.2M | $3.0M |
| Operating income | -$5.3M | -$5.1M | -$6.4M | -$7.2M | -$4.5M | -$7.5M | -$2.7M | -$2.4M | -$1.5M | -$954.6K |
| Interest expense | — | — | — | — | — | $367 | $9 | $47 | $37 | $282 |
| Pre-tax income | -$3.8M | -$5.0M | -$5.9M | -$7.1M | -$4.5M | -$7.4M | -$2.7M | -$2.4M | -$1.4M | -$908.6K |
| Income tax | $23.0K | $1.0K | $42.0K | $51.0K | $24.0K | $13.1K | $7.4K | $24.2K | $31.8K | — |
| Net income | -$3.8M | -$5.0M | -$6.0M | -$7.1M | -$4.5M | -$7.4M | -$2.7M | -$2.4M | -$1.5M | -$908.6K |
| EPS, basic | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 | -0.62 | -0.26 | -0.26 | -0.17 | -0.11 |
| EPS, diluted | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 | -0.62 | -0.26 | -0.26 | -0.17 | -0.11 |
| Shares, diluted (wtd. avg.) | $2.9M | $2.3M | $2.1M | $14.2M | $12.7M | $11.9M | $10.2M | $9.2M | $8.6M | $8.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M | $4.2M | $8.6M | $686.8K | $1.2M | $1.2M |
| Receivables | $785.0K | $731.0K | $947.0K | $722.0K | $774.0K | $1.5M | $1.8M | $1.5M | $799.9K | $1.1M |
| Inventory | $1.7M | $1.5M | $2.4M | $2.1M | $2.4M | $3.2M | $2.9M | $2.2M | $2.2M | $1.7M |
| Total current assets | $4.0M | $4.9M | $7.7M | $12.8M | $9.4M | $9.2M | $14.8M | $4.5M | $4.5M | $4.2M |
| Property, plant and equipment | $78.0K | $135.0K | $201.0K | $213.0K | $214.0K | $310.5K | $279.4K | $351.1K | $351.1K | $331.9K |
| Other intangibles | $209.0K | $228.0K | $212.0K | $165.0K | $170.0K | $294.8K | $168.7K | $107.2K | $98.9K | $174.5K |
| Total assets | $6.8M | $5.9M | $9.3M | $14.5M | $11.4M | $11.8M | $17.3M | $5.2M | $5.2M | $5.0M |
| Accounts payable | $377.0K | $295.0K | $560.0K | $344.0K | $736.0K | $431.0K | $833.4K | $1.0M | $687.0K | $352.0K |
| Total current liabilities | $2.5M | $1.7M | $2.2M | $1.9M | $2.0M | $1.3M | $1.5M | $1.3M | $896.8K | $528.9K |
| Total liabilities | $4.1M | $1.8M | $2.7M | $2.7M | $3.0M | $2.6M | $3.0M | $1.3M | — | — |
| Retained earnings | -$56.9M | -$53.2M | -$48.2M | -$42.2M | -$35.1M | -$30.5M | -$23.1M | -$19.6M | -$17.2M | -$15.7M |
| Total equity | $2.6M | $4.1M | $6.6M | $11.7M | $8.3M | $9.2M | $14.2M | $4.0M | $4.3M | $4.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$479.0K | -$5.3M | -$4.3M | -$2.2M | -$1.2M | -$722.9K |
| Depreciation and amortisation | — | — | — | $84.0K | $339.0K | $105.0K | $105.3K | $101.2K | $111.1K | $144.9K |
| Stock-based compensation | $476.0K | $460.0K | $837.0K | $1.2M | $1.3M | — | — | — | — | — |
| Capital expenditure | — | — | $51.0K | $64.0K | $57.0K | $135.9K | $33.6K | $101.1K | $130.3K | $96.1K |
| Investing cash flow | -$1.0K | -$37.0K | -$115.0K | -$78.0K | -$170.0K | -$295.6K | -$118.9K | -$171.1K | -$130.3K | -$96.1K |
| Financing cash flow | $2.3M | $2.1M | -$81.0K | $9.4M | $2.4M | $1.1M | $12.4M | $1.9M | $1.3M | $157.7K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-040851.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.59B | 29.6x | 0.5% |
| CLDX | Celldex Therapeutics, Inc. | $3.12B | — | -78.0% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $958.0M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| TKNO | Alpha Teknova, Inc. | $371.5M | — | 7.4% |